NINLARO

NINLARO is the brand name for ixazomib and is available as an oral capsule.

NINLARO is available as a 2.3 mg, 3 mg, and 4 mg oral capsule.

NINLARO is an anticancer agent and is used to treat multiple myeloma in people whose cancer came back after receiving anticancer treatments.

NINLARO is a type of targeted therapy known as a proteasome inhibitor. It works by blocking a group of proteins, called proteasomes, inside cancer cells. Typically, proteasomes help cells break down proteins that they no longer need. When NINLARO blocks proteasomes from working, cell waste builds up, which causes cancer cells to die.

NINLARO is typically taken along with lenalidomide (Revlimid) and dexamethasone. The typical starting dose is to take 4 mg of NINLARO by mouth once a week during the first 3 weeks (on days 1, 8, and 15) of a 4-week treatment cycle. Your dose of NINLARO might be different if you’re taking other medications that might interact with NINLARO, or have liver or kidney problems.

NINLARO is a safe and effective treatment when used for FDA licensed indications. However, like all medications, they may give you unwanted side effects. You should always discuss potential side effects with your physician to ensure the medication is suitable and right for you.

Common side effects of NINLARO:

• Low platelet count
• Low white blood cell count
• Diarrhea
• Constipation
• Nausea
• Nerve pain (peripheral neuropathy)
• Back pain
• Sore throat, runny nose, and other symptoms of sinus or throat infections
• Rash
• Swelling of arms and legs
• Vomiting

Serious side effects are rare with NINLARO. Contact your healthcare provider immediately if you experience any of the following.

• Severe loss of fluids and electrolytes: dizziness, confusion, fainting, feeling tired, feeling thirsty, dry skin, vomiting or diarrhea that’s difficult to stop, not making much urine
• Serious blood clots in small arteries: tiredness, nausea, vomiting, bruising, rash-like patches on the skin, nosebleeds, blood in the urine, pale skin
• Serious liver problems: tiredness, loss of appetite, nausea or vomiting, dark urine, stomach pain, yellowing of the eyes or skin
• Serious skin reactions: new or worsening rash, severe blistering or peeling of your skin, mouth sores

The following medications may interact with NINLARO:

• Strong CYP3A inducers: Avoid concomitant use with NINLARO

Takeda Pharmaceuticals

NINLARO can harm your unborn baby. For females, avoid becoming pregnant during treatment with NINLARO. Your healthcare provider will do a pregnancy test before you start treatment with NINLARO. You should use effective non-hormonal birth control during treatment and for 90 days after your last dose of NINLARO. If using hormonal contraceptives (for example, birth control pills), you should also use an additional barrier method of contraception (for example, diaphragm or condom). Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with NINLARO. Males with female partners who are able to become should use effective birth control during treatment and for 90 days after your last dose of NINLARO. Tell your healthcare provider right away if your partner becomes pregnant or thinks she may be pregnant while you are being treated with NINLARO.